1269232-93-0

Usage

Uses

Used in Food Industry:
Benzoic acid, 3-bromo-5-chloro-2-fluoro-, is used as a preservative in the food industry to extend the shelf life of products by inhibiting the growth of bacteria, yeast, and molds. Its effectiveness as a preservative is attributed to its ability to penetrate microbial cell walls and disrupt cellular metabolism.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, benzoic acid, 3-bromo-5-chloro-2-fluoro-, is used in the production of various medications. Its antimicrobial properties make it suitable for preserving the stability and safety of pharmaceutical formulations. Additionally, it may be used as an intermediate in the synthesis of other pharmaceutical compounds.
Used in Personal Care Products:
Benzoic acid, 3-bromo-5-chloro-2-fluoro-, is also used as a preservative in personal care products such as cosmetics, lotions, and creams. It helps maintain the freshness and safety of these products by preventing the growth of harmful microorganisms.
Used in Agrochemicals Production:
Benzoic acid, 3-broMo-5-chloro-2-fluorois utilized in the production of agrochemicals, specifically as a precursor in the synthesis of various pesticides and herbicides. Its presence in these products contributes to their effectiveness in controlling pests and weeds in agricultural settings.
Used in Organic Compounds Synthesis:
Benzoic acid, 3-bromo-5-chloro-2-fluoro-, has potential uses in the synthesis of organic compounds for research purposes. Its unique structure with multiple substituents allows for further chemical reactions and modifications, making it a valuable building block in organic chemistry.
Used in Research for Biological Activity:
Due to its unique structure and potential biological activity, benzoic acid, 3-bromo-5-chloro-2-fluoro-, is of interest for research purposes. Scientists may study its interactions with biological systems to explore its potential applications in medicine, agriculture, or other fields.

Upstream product

• 1269440-82-5 3-bromo-5-chloro-2-fluorobenzaldehyde 
• 1996-30-1 2-bromo-4-chloro-1-fluorobenzene 
• 124-38-9 carbon dioxide 

Downstream Products

• 1269232-94-1 tert-butyl 3-bromo-5-chloro-2-fluorophenyl-carbamate 
• 1269232-95-2 3-bromo-5-chloro-2-fluoroaniline 
• 1269440-69-8 tert-butyl 5-chloro-2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylcarbamate: 
• 1269440-09-6 methyl N-[(2S)-1-[(4-{3-[5-chloro-2-fluoro-3-(propane-1-sulfonamido)phenyl]-1-(propan-2-yl)-1H-pyrazol-4-yl}pyrimidin-2-yl)amino]propan-2-yl]carbamate 
• 1269440-77-8 (S)-methyl 1-(4-(3-(5-chloro-2-fluoro-3-(tert-butoxycarbonylamino)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ylcarbamate 
• 1269440-78-9 (S)-methyl 1-(4-(3-(3-amino-5-chloro-2-fluorophenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ylcarbamate 
• 1269440-17-6 methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate 
• 1269440-99-4 (S)-methyl 1-(4-(3-(5-chloro-2-fluoro-3-(N-(methylsulfonyl)methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ylcarbamate 
• 1353575-28-6 methyl-5-chloro-2-fluoro-3-pivalamidobenzoate 
• 1353575-61-7 N-(5-chloro-2-fluoro-3-(2-(2-(methylthio)pyrimidin-4-yl)acetyl)phenyl)pivalamide 
• 1353575-59-3 N-(3-(2-bromo-2-(2-(methylthio)pyrimidin-4-yl)acetyl)-5-chloro-2-fluorophenyl)pivalamide 
• 1353576-03-0 N-(3-(2-amino-5-(2-(methylthio)pyrimidin-4-yl)thiazol-4-yl)-5-chloro-2-fluorophenyl)pivalamide 
• 1353576-04-1 N-(3-(2-bromo-5-(2-(methylthio)pyrimidin-4-yl)thiazol-4-yl)-5-chloro-2-fluorophenyl)pivalamide 
• 1353576-05-2 N-(5-chloro-3-(2-cyclopropyl-5-(2-(methylthio)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)pivalamide 

Relevant academic research and scientific papers

Development of a Potent Brain-Penetrant EGFR Tyrosine Kinase Inhibitor against Malignant Brain Tumors

The epidermal growth factor receptor (EGFR) is genetically altered in nearly 60% of glioblastoma tumors; however, tyrosine kinase inhibitors (TKIs) against EGFR have failed to show efficacy for patients with these lethal brain tumors. This failure is attributed to the inability of clinically tested EGFR TKIs to cross the blood-brain barrier (BBB) and achieve adequate pharmacological levels to inhibit various oncogenic forms of EGFR that drive glioblastoma. Through SAR analysis, we developed compound 5 (JCN037) from an anilinoquinazoline scaffold by ring fusion of the 6,7-dialkoxy groups to reduce the number of rotatable bonds and polar surface area and by introduction of an ortho-fluorine and meta-bromine on the aniline ring for improved potency and BBB penetration. Relative to the conventional EGFR TKIs erlotinib and lapatinib, JCN037 displayed potent activity against EGFR amplified/mutant patient-derived cell cultures, significant BBB penetration (2:1 brain-to-plasma ratio), and superior efficacy in an EGFR-driven orthotopic glioblastoma xenograft model.

Compounds and Compositions as Protein Kinase Inhibitors

The present invention provides compounds of Formula I or II: wherein R1, R1b, R2, R3, R4, R5, R6 and R7 are defined herein. The compounds of Formula (I) or (II) and pharmaceutical compositions thereof are useful for the treatment of B-Raf-associated diseases.

HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

The present invention provides compounds of Formula (I): wherein R1, R2, R3, and X are as defined herein. The compounds of Formula (I) and pharmaceutical compositions thereof are useful for the treatment of cancer, and B-

COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

The invention provides a novel class of compounds of formula 1, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.